And it will happen just that fast.........no warning........and for those sitting along the sidelines with Sean Williams............oh well...............tough shitzzzzzzzzzzzzzzz
Five "Thumbs Down"...nice...you guys are either too foooookin' stupid to answer the question or have no sense of humor ......we need to add a little levity to this MB; and as a bit of advice.....get of life..........long / short, basher / pumper......chill out.....................
Below is a question for those of you about to take this year's Final Exam in “Investing 101”. It appears some of you got the answer incorrect on last year’s exam.
Question: What does the abbreviation “MM” stand for in stock market terminology?
A) Market Monster
B) Mr. Market
C) Market Maker
D) Market Manipulator
E) All of the Above.
F) None of the Above.
Good luck……and remember………no cheating…………
I know you are "just doing your job", but that post is about as low as one can go. You see, people with a heart, soul and conscience, actually share their personal experiences (including hardships) with others; it's part of the healing process. I actually feel sorry for you; it must be very lonely to be such a ruthless and selfish "being" such as yourself.
What's your interest in GALE - you've never posted here before and only 2 posts (both in 2015) since you became a YMB member in 2007? Can you say "soft basher".............bye, bye................
If you go to Orexo's website and go to their "Interim Report January - June 2015", the detail on royalties is on page 8 of the report. Interesting observation....two entries..one for "Abstral Royalities" and one for "Fixed Royalty Abstral". If I read it correctly, the YTY "fixed royalties" went down and "royalties" went up.....good for GALE. Also, From what I saw on page 19 was the last page of the report and had a bunch of CYA footnotes on it.......
Not sure what the enrollment breakdown was by country for PRESENT Trial, but clearly the high frequency of cancer (and I am assuming recurrence) could have a major impact on reaching the 70th event.
The countries with the top 20 highest incidence of breast cancer in 2012 are given in the table below.
• Belgium had the highest rate of breast cancer, followed by Denmark and France.
• Slightly more cases of breast cancer were diagnosed in less developed countries (53%).
• The highest incidence of breast cancer was in Northern America and Oceania; and the lowest incidence in Asia and Africa.
Rank Country Age-Standardised Rate per 100,000 (World)
1 Belgium 111.9
2 Denmark 105.0
3 France (metropolitan) 104.5
4 The Netherlands 99.0
5 Bahamas 98.9
6 Iceland 96.3
7 United Kingdom 95.0
8 Barbados 94.7
9 United States of America 92.9
10 Ireland 92.3
11 French Polynesia 92.2
12 Germany 91.6
13 Italy 91.3
14 Finland 89.4
15 Luxembourg 89.1
16 New Caledonia 87.6
17 Australia 86.0
18 Malta 85.9
19 New Zealand 85.0
20 Switzerland 83.1
OK....if your Euro patients data is accurate, then I agree. Don't you think Galena took that into account when they came out with their Q4 /Q1 prediction date? I can't believe they would overlook something that obvious.
You realize that may not be a good thing because it will likely include more NeuVax recipients than we'd like to see..............
9:30 am Nymox Pharma announces that its U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate for BPH have successfully met the pre-specified primary endpoint (shares halted) (NYMX) : The co announced that its U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 of fexapotide triflutate (NX-1207) for BPH have successfully met the pre-specified primary endpoint of long-term symptomatic statistically significant benefit superior to placebo. Fexapotide showed an 'excellent' safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side effects in the 2 studies (n=978).
The Company now intends to meet with authorities and to proceed to file where possible in due course for regulatory approvals for fexapotide triflutate in various jurisdictions and territories.
The primary endpoint variable of the long-term study was improvement in the AUA BPH Symptom Score which was statistically significant (p
Highlights of the pivotal Phase 3 extension top-line results include:
Median duration of 3.5 years from a single injection treatment mean improvement of 5.3 points in AUA BPH Symptom Score. Statistically significant (mean p
Mean improvement of 7.1 points in AUA BPH Symptom Score (primary endpoint variable) after median duration of 3.5 years in first-line BPH treatment of fexapotide treated subjects (p)
A company with 2 FDA approved drugs on the market, a potential blockbuster in Phase3 and 2 others in Phase 2 and we're tanking down to $1.50....................Clearly the shorts and MM's are in control and all we can do is sit by and watch......this really sucks.................
Given the recent favorable PHASE 2 data presented on 301 & 401 in Chicago and Vienna, shouldn't they be receiving FDA approval very soon to move into Phase 3 on both?
Puma's legal issues are going to drag them down just they did at GALE; except in triple-digit dollars, not single-digit dollars as was the case with GALE...........IMHO............
......to Dan's point, these ambulance chaser's make more money in law suits than they would in politics. A few biotech suits currently in process are SNSS, PUMA, VTL and HEB just agreed to pay $2.75M......you can only imagine how much of that went to the lawyers versus to the shareholders..........what a joke....
....based on several posts. In this case, there may something to be said about the "element of surprise" by announcing it at the eanrings call..............IMHO....................
I posed the very question to Remy by email (launch scheduled for July) and I have not heard back from her, which is not like her. She always replies to my email quite promptly, so I suspect she can't reply saying it's not available (because it is) and she can't say the launch has occurred as that would let the cat out of the bag. I would expect a PR release next week or news announced on the earnings call. I have problem with them announcing it on the earnings call, along with some actual sales as icing on the cake.
Absolutely.... The Sean Williams approach (recommendation) to "sit on the sidelines" is azzzzzinine as the train will have already left the station and they will miss the big jump.